Skip to main content

Table 5 The changes of laboratory examination data between pre- and post-TAE status

From: Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study

Variable   pre-TAE
n=5 (%)
post-TAE
n=5 (%)
p value
AST (IU/l)   73.8 ± 28.0 32.2 ± 13.5 0.017
ALT (IU/l)   44.2 ± 20.4 27.8 ± 14.3 0.180
Total Bilirubin (mg/dl)   0.74 ± 0.36 0.54 ± 0.29 0.359
Albumin (g/dl)   3.80 ± 0.77 3.84 ± 0.15 0.913
PT-INR   1.08 ± 0.07 1.08 ± 0.05 0.959
Platelet count (/μl)   37.8 ± 14.1 21.9 ± 6.0 0.049
ICG-R15 (%)   13.6 ± 2.6 14.9 ± 6.3 0.676
Child-Pugh A 5 (100.0) 5 (100.0) 0.999
AFP (ng/ml)   2907.2 ± 6313.9 20.5 ± 33.2 0.337
AFP-L3 (%)   2.5 ± 4.6 3.7 ± 5.3 0.719
PIVKA-II (mAU/ml)   43019.0 ± 29839.0 5142.0 ± 10622.0 0.028
  1. Consequent values are expressed as means ± standard errors
  2. TAE trans-arterial embolization, AST aspartate aminotransferase, ALT alanine aminotransferase, PT-INR prothrombin time-international normalized ratio, ICG-R15 indocyanine green retention15, AFP alpha-fetoprotein, AFP-L3 L3 fraction of alpha-fetoprotein, PIVKA-II protein-induced vitamin K absence or antagonist-II